The global demand for Gadopentetate Dimeglumine Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028. Regarding volume, the market was calculated XX Kilo Tons in 2021 and forecast to touch XX Kilo Tons by 2028 with a CAGR of XX% during 2022-2028.
Gadopentetate dimeglumine is the contrast media that is N-methylglucamine salt of the gadolinium complex of diethylenetriamine pentaacetic acid. It is injected in the body before magnetic resonance imaging (MRI) in adults and pediatric patients to facilitate the clear visualization of lesions with abnormal vascularity in the neck and head. In addition, it allows blood vessels, organs, and other non-bony tissues to be seen more precisely and helps diagnose particular brain, blood vessels, and spin disorders. Gadopentetate dimeglumine is sold under brand name Magnevist.
Magnetic resonance imaging is performed globally to diagnose diseases. It is preferred by most healthcare professionals, as it provides a primary diagnosis in a short time. Magnetic resonance imaging is identified as an effective and quick diagnostic procedure. In recent years, chronic and severe disease prevalence associated with head and neck has grown, resulting in MRI requirements, thus gadopentetate dimeglumine. The other key factors propelling the growth of the gadopentetate dimeglumine market are an increase in technological advancements, such as MRI with PET or CT, rising adoption of MRI in developing countries, and the rising insurance penetration in the developed and developing markets. However, the availability of other competitive contrast agent such as gadolinium, hepatobiliary, iron oxide, iron platinum, and others hampers the market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gadopentetate dimeglumine. The growth and trends of Gadopentetate Dimeglumine Industry provide a holistic approach to this study.
This section of the gadopentetate dimeglumine market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
- 10ml: 4.69g
- 12ml: 5.63g
- 15ml: 7.04g
This section covers the regional outlook, which accentuates current and future demand for the Gadopentetate Dimeglumine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Gadopentetate Dimeglumine Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gadopentetate dimeglumine market include Takeda, Pfizer, AstraZeneca, Bayer, Sun Pharma, Teva, Eisai Co., Mylan, AOSAIKANG Pharma, Luoxin Pharma, LIVZON, Eastchina Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.